Home > Oncology > SABCS 2021 > Triple-Negative Breast Cancer > Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10

Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10

Presented By
Dr Javier Cortés, Vall d'Hebron Institute of Oncology, Spain

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, KEYNOTE-355
Combined positive score (CPS) ≥10 is a reasonable cut-off to define patients with metastatic triple-negative breast cancer who benefit from pembrolizumab plus chemotherapy, subgroup analyses of KEYNOTE-355 show. In the phase 3 KEYNOTE-355 trial (NCT02819518), first-line pembrolizumab combined with chemotherapy showed statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared with placebo plus chemotherapy in patients with previously untreated, locally recurrent, inoperable, or metastatic TNBC whose tumours expressed PD-L1 with a CPS ≥10 [1]. Additional analyses were done in subgroups of patients by additional CPS cut-offs to the primary results of KEYNOTE-355. Dr Javier Cortés (Vall d'Hebron Institute of Oncology, Spa...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on